IFNAR2 and COVID-19: As IFNAR2 is expressed on circulating immune cells, to clarify the mechanism by which IFNAR2 p.F8S predisposes individuals to severe COVID-19, we next investigated the impact of the p.F8S variant on the immune cell transcriptome during SARS-CoV-2 infection in 57 patients with severe disease from the FOGS cohort (of whom n = 8 were carriers of p.F8S—heterozygous, n = 7; homozygous, n = 1), whose PBMCs were collected at the peak of infection during hospitalization.